Arbor Biotechnologies
arbor.bio
Actively hiring
Cell & Gene Therapy
Health Care
Biotechnology
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
201-500
employees, estimated range
Hiring now
2
+1 posted in 30 days
Backers
2
ARCH Venture Partners, Illumina Ventures
Momentum
13/100
hiring for its size
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Hacker News stories
1
best: 1 points
Backed byfrom the funds' portfolios and accelerator catalogs
ARCH Venture Partners Similar startupsby what they do, their industry and backers
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
At Jaguar Gene Therapy, we believe in a world where patients and families won’t have to hear those words. Our mission is to accelerate…
About Us We build the medicines we wish existed CPTx is a genetic medicines company redefining how we treat disease using immune-silent…
Alia Therapeutics is a startup which is developing next-generation gene editing medicines to cure genetic diseases.
Instant Quantification of genetic modifications for Cell and Gene Therapies.
Profluent is a company founded in 2022 that trains large language models on protein sequences to design new functional proteins. It…
News
Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria
PARMA, Italy & CAMBRIDGE, MA, June 25, 2026 - Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicine
Read more
Report
Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer
CAMBRIDGE, MA - May 18, 2026 - Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mathew Pletcher, Ph.D., as Chief Scientific Officer, succeeding Joh
Read more
Report
Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases
CAMBRIDGE, MA - May 12, 2026 - Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announces the presentation of data demonstrating the first precise in vivo genome editing in the
Read more
Report
Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
CAMBRIDGE, MA - April 27, 2026 - Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced three upcoming presentations at the 2026 American Society of Gene and Cell Therapy (
Read more
Report
Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines
INCHEON, Korea - October 30, 2025 - Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, today announced an equity investment in Arbor Bi
Read more
Report
Pro access
Upgrade to see all 20 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Salary insights
Compensation ranges based on this company's open jobs
Median
$178k
Typical range
$120k – $235k
Open positions
2
2
Jobs
Junior
50%
Architect
50%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 1 | $120k | $120k |
| Architect | 1 | $235k | $235k |
Highest paying role
Director, Regulatory Affairs
$235k
Normalized to USD per year
Growth
Hiring Momentum
28/100
Slowing
Open positions
2
0 opened / 0 closed in 30 days
ATS activity
Every ~1 days
09/29/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Public Policy
50% ▲
Science & Research
50% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Cambridge
Cambridge
United States
HQ
Arbor Biotechnologies
2 open roles 2 posted in 90 days 50% engineering 200-500 est. staff $178k Avg Salary
hires for Public Policy, Science & Research
20 Acorn Park Drive, Suite 500, Cambridge, MA 02140